(Natural News) A new study finds that cultivation and enrichment of microbes on the face can infiltrate the lungs through unconscious aspirations and cause inflammatory responses and advanced stage lung cancer. The nose and the mouth were designed to take in oxygen without strain, uninhibited. The oxygen travels down the trachea and splits off into two tubes called the bronchi. From there, the oxygen travels down a series of bronchioles until it reaches the alveoli, which are tiny air sacs covered with blood vessels. These air sacs take the oxygen directly to the heart, where it is dispersed throughout the body.

When a person exhales, the process is put in reverse and the lungs exhale carbon dioxide. This carbon dioxide gas is the vehicle that allows the organ systems to rid the body of wastes. When this process is obstructed or restrained for prolonged periods of time, the lungs and the heart struggle to nourish the rest of the body. Long term mask wearing also hinders the body’s natural ability to detoxify wastes, creates an acidic environment, and slowly strains the organ systems throughout the body.

Masks are priming the lungs for inflammation and lung cancer pathology

A study published in the journal Cancer Discovery finds that lung cancer progresses when the lungs are forced to regurgitate microbes. Prolonged mask use creates a moist environment that cultivates microbes. This toxic environment not only forces the person to regurgitate their own wastes, but also inundates the lungs with microbes that cause a toxic environment that feeds lung cancer.

The researchers found that the lungs are not just a sterile environment. When microbes inundate the lungs, they can active an immune response. This causes inflammatory proteins such as the cytokine IL-17 to appear.

Microbes that are normally found in the mouth can make their way into the lungs. “Given the known impact of IL-17 and inflammation on lung cancer, we were interested in determining if the enrichment of oral commensals in the lungs could drive an IL-17-type inflammation and influence lung cancer progression and prognosis,” said Leopoldo Segal, Director of the Lung Microbiome Program and Associate Professor of Medicine, New York University Grossman School of Medicine.